Previous close | 41.88 |
Open | 36.50 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 35.67 - 39.65 |
52-week range | 13.89 - 43.04 |
Volume | |
Avg. volume | 681 |
Market cap | 2.245B |
Beta (5Y monthly) | 1.29 |
PE ratio (TTM) | 4.46 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN DIEGO, July 11, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results.
SAN DIEGO, June 22, 2024--Tandem Diabetes Care today presented positive real-world data from a Tandem Mobi user satisfaction survey at the 2024 ADA Scientific Sessions.
SAN DIEGO, June 20, 2024--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management.